Merck’s Prevymis Set To Expand Into Renal Transplant CMV Prevention
Possible New Option
The major’s antiviral has hit the mark in a late-stage study of CMV disease prevention in the post kidney transplant setting, triggering plans for a US filing to expand its indication from stem cell transplant patients.
You may also be interested in...
Takeda’s Maribavir Post-Transplant CMV Indication Should Not Be Limited By Resistance, US Panel Says
Advisory committee unanimously endorses novel antiviral for treatment of post-transplant patients with refractory/resistant cytomegalovirus infection, and in the process rejects US FDA’s proposal to distinguish target population based upon genetic resistance.
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.
The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.